Ovid Technologies

Ovid Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing impactful medicines for patients with rare neurological disorders. The company's lead program, soticlestat (TAK-935), is a potent and highly selective inhibitor of the enzyme cholesterol 24-hydroxylase, currently in Phase 3 development for Dravet syndrome and Lennox-Gastaut syndrome in collaboration with Takeda. Ovid's pipeline also features OV329, a GABA aminotransferase inhibitor for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter for status epilepticus. By targeting specific pathways in the central nervous system, Ovid aims to address significant unmet needs in epilepsy and other neurodevelopmental conditions. The company leverages a deep understanding of neuronal signaling to identify and advance novel mechanisms of action for orphan CNS diseases.